May 25, 2023 C-Path Welcomes Red Nucleus Clinical C-Path is proud to welcome Red Nucleus Clinical as the newest member of its Electronic Clinical Outcome Assessment (eCOA) Consor
May 24, 2023 Improving the Design of Clinical Trials in T1D: Analysis of Data from the Trial Outcome Markers Initiative (TOMI) Collaboration With presentations from JDRF, TrialNet and the TOMI-T1D Collaboration The Trial Outcome Marker Initiative brings together data fro
May 4, 2023 Results of the 2022 global WHO online survey on diagnostic capacities and treatment practices for implantation (deep) mycoses Barbara Milani (WHO consultant), under the guidance of Daniel Argaw Dagne (WHO Department of Control of Neglected Tropical...
May 4, 2023 A Path to Real-World Evidence in Critical Care Using Open-Source Data Harmonization Tools COVID-19 highlighted the need for use of real-world data (RWD) in critical care as a near real-time resource for clinical...
May 3, 2023 Video: Brief TRxA Overview In this video, TRxA Executive Director Maaike Everts and Associate Director Michelle Morgan give viewers a short overview of the..
May 2, 2023 C-Path’s CDRC Meeting Highlights the Importance of Drug Repurposing The Critical Path Institute’s CURE Drug Repurposing Collaboratory and FDA hosted their annual meeting April 18-20 to bring toget
April 27, 2023 View Now | Clinical Outcome Assessments: Does one size fit all? Join C-Path’s Rare Disease Cures Accelerator-Data and Analytics Platform and its Rare Disease Clinical Outcome Assessment
April 27, 2023 Clinical Outcome Assessments: Does one size fit all? This webinar is presented jointly by the Rare Disease COA Consortium and C-Path’s Rare Disease Cures Accelerator-Data and...
April 26, 2023 C-Path Europe: A Global Vision of Success TUCSON, Ariz. and AMSTERDAM, April 26, 2023 — As an organization that generates regulatory-endorsed solutions and methodologies
April 25, 2023 Approaches to the Assessment of Clinical Benefit of Treatments for Conditions That Have Heterogeneous Symptoms and Impacts Evaluating the clinical benefit of interventions aimed at treating conditions with heterogeneous symptom....